File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Initial treatment with lansoprazole in young dyspeptic patients with negative urea breath test result: A randomized controlled trial with 12-month follow-up

TitleInitial treatment with lansoprazole in young dyspeptic patients with negative urea breath test result: A randomized controlled trial with 12-month follow-up
Authors
Issue Date2007
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.html
Citation
American Journal Of Gastroenterology, 2007, v. 102 n. 7, p. 1483-1488 How to Cite?
AbstractINTRODUCTION: Although empirical antisecretory drug therapy is recommended to young dyspeptic patients without alarming features, the effectiveness of this approach remains undetermined. We evaluated the long-term effects of an initial 12-wk course of lansoprazole in young dyspeptic patients without Helicobacter pylori (H. pylori) infection. METHODS: Patients who were less than 45 yr and presented with at least 3 months of dyspepsia in the absence of alarming features were eligible. They were offered 13C-urea breath test (UBT) to determine H. pylori status and all symptomatic patients with negative UBT were randomized to receive lansoprazole 30 mg daily or placebo for 12 wk. Those who had previous endoscopy or positive UBT were excluded. Primary end point was the proportion of patients with treatment failure, defined as worsening of global dyspeptic symptom, while on study medication. Patients were followed up for 26 wk for global dyspeptic symptom as determined by 7-point Likert scale. Quality-of-life assessment (SF-36), need of endoscopy, and utilization of other health-care services were monitored for 52 wk. RESULTS: A total of 157 dyspeptic patients were randomized. At the end of 12-wk treatment, the proportion of patients with treatment failure was similar in the lansoprazole (33.3%) and placebo (30.3%) groups (P = 0.74). Patients' global assessment of their dyspeptic symptom was comparable at all time points measured. There was also no significant difference in the SF-36 mental and physical summary scales. At the end of 52 wk, there was no difference in the proportion of patients who underwent endoscopy, had additional medical consultations, or used other nonstudy medications between the two groups. CONCLUSION: Lansoprazole is not effective in the initial management of young dyspeptic patients without H. pylori infection. © 2007 by Am. Coll. of Gastroenterology.
Persistent Identifierhttp://hdl.handle.net/10722/163088
ISSN
2015 Impact Factor: 10.383
2015 SCImago Journal Rankings: 3.946
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, WKen_US
dc.contributor.authorWu, JCYen_US
dc.contributor.authorChan, FKLen_US
dc.contributor.authorFung, SSLen_US
dc.contributor.authorWong, VWSen_US
dc.contributor.authorHui, AJen_US
dc.contributor.authorHung, LCTen_US
dc.contributor.authorSung, JJYen_US
dc.date.accessioned2012-09-05T05:27:25Z-
dc.date.available2012-09-05T05:27:25Z-
dc.date.issued2007en_US
dc.identifier.citationAmerican Journal Of Gastroenterology, 2007, v. 102 n. 7, p. 1483-1488en_US
dc.identifier.issn0002-9270en_US
dc.identifier.urihttp://hdl.handle.net/10722/163088-
dc.description.abstractINTRODUCTION: Although empirical antisecretory drug therapy is recommended to young dyspeptic patients without alarming features, the effectiveness of this approach remains undetermined. We evaluated the long-term effects of an initial 12-wk course of lansoprazole in young dyspeptic patients without Helicobacter pylori (H. pylori) infection. METHODS: Patients who were less than 45 yr and presented with at least 3 months of dyspepsia in the absence of alarming features were eligible. They were offered 13C-urea breath test (UBT) to determine H. pylori status and all symptomatic patients with negative UBT were randomized to receive lansoprazole 30 mg daily or placebo for 12 wk. Those who had previous endoscopy or positive UBT were excluded. Primary end point was the proportion of patients with treatment failure, defined as worsening of global dyspeptic symptom, while on study medication. Patients were followed up for 26 wk for global dyspeptic symptom as determined by 7-point Likert scale. Quality-of-life assessment (SF-36), need of endoscopy, and utilization of other health-care services were monitored for 52 wk. RESULTS: A total of 157 dyspeptic patients were randomized. At the end of 12-wk treatment, the proportion of patients with treatment failure was similar in the lansoprazole (33.3%) and placebo (30.3%) groups (P = 0.74). Patients' global assessment of their dyspeptic symptom was comparable at all time points measured. There was also no significant difference in the SF-36 mental and physical summary scales. At the end of 52 wk, there was no difference in the proportion of patients who underwent endoscopy, had additional medical consultations, or used other nonstudy medications between the two groups. CONCLUSION: Lansoprazole is not effective in the initial management of young dyspeptic patients without H. pylori infection. © 2007 by Am. Coll. of Gastroenterology.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.htmlen_US
dc.relation.ispartofAmerican Journal of Gastroenterologyen_US
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazoles - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAge Factorsen_US
dc.subject.meshCarbon Isotopes - Diagnostic Useen_US
dc.subject.meshDiagnosis, Differentialen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDyspepsia - Diagnosis - Drug Therapy - Psychologyen_US
dc.subject.meshEndoscopy, Gastrointestinalen_US
dc.subject.meshEnzyme Inhibitors - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshProton Pumps - Antagonists & Inhibitorsen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshTime Factorsen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshUrea - Diagnostic Useen_US
dc.titleInitial treatment with lansoprazole in young dyspeptic patients with negative urea breath test result: A randomized controlled trial with 12-month follow-upen_US
dc.typeArticleen_US
dc.identifier.emailLeung, WK:waikleung@hku.hken_US
dc.identifier.authorityLeung, WK=rp01479en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1572-0241.2007.01229.xen_US
dc.identifier.pmid17593161-
dc.identifier.scopuseid_2-s2.0-34250808021en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34250808021&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume102en_US
dc.identifier.issue7en_US
dc.identifier.spage1483en_US
dc.identifier.epage1488en_US
dc.identifier.isiWOS:000247474100022-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLeung, WK=7201504523en_US
dc.identifier.scopusauthoridWu, JCY=7409253910en_US
dc.identifier.scopusauthoridChan, FKL=7202586434en_US
dc.identifier.scopusauthoridFung, SSL=7201970030en_US
dc.identifier.scopusauthoridWong, VWS=7202525502en_US
dc.identifier.scopusauthoridHui, AJ=7102453674en_US
dc.identifier.scopusauthoridHung, LCT=7103351774en_US
dc.identifier.scopusauthoridSung, JJY=36847007300en_US
dc.identifier.citeulike1412545-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats